Trial Profile
Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary) ; Nitrogen; Oxygen
- Indications COVID 2019 infections; Hypoxaemia; Respiratory insufficiency
- Focus Adverse reactions
- Acronyms NO-COVER
- 17 Aug 2020 Planned End Date changed from 15 Jan 2021 to 15 Jul 2021.
- 17 Aug 2020 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2021.
- 17 Aug 2020 Planned initiation date changed from 1 Jul 2020 to 1 Dec 2020.